ABEO stock information

Sector:

Healthcare

Description:

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Abeona Therapeutics Inc. website

Current Price

$3.31

RSI

72.01

Market Capitalization:

22.4M

Beta:

1.047

Volume:

237,586

Analyst Target Price:

$ 42.33

Economiic Fair Price:

Earnings DateNovember 21, 2022

Report DateNovember 14, 2022

QuarterQ3

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash

Debt

EPS38.68

Profit MarginN/A

Revenue Per Share TTM0.882

Return On Equity TTM-1.59

2021 Revenue

$ 3M

-70.00 %

2020 Revenue

$ 10M

233.56 %

2018 Revenue

$ 3M

258.18 %

2017 Revenue

$ 837K

-5.85 %

2016 Revenue

$ 889K

2021 Free Cash Flow

$ -69.8M

-92.04 %

2020 Free Cash Flow

$ -36.4M

47.56 %

2019 Free Cash Flow

$ -69.3M

-18.30 %

2018 Free Cash Flow

$ -58.6M

-146.29 %

2017 Free Cash Flow

$ -23.8M

-75.83 %

2016 Free Cash Flow

$ -13.5M

2021 Pre Tax Income

$ -84.9M

-0.83 %

2020 Pre Tax Income

$ -84.2M

-48.64 %

2018 Pre Tax Income

$ -56.7M

-107.44 %

2017 Pre Tax Income

$ -27.3M

-24.90 %

2016 Pre Tax Income

$ -21.9M

Abeona Therapeutics Inc.(ABEO)